Hope Rugo

Hope S. Rugo is professor of medicine and the director of the breast oncology clinical trials program at the University of California at San Francisco, and an investigator of SPORE (Specialized Program of Research Excellence in Breast Cancer) in the Bay Area.

In 2014 Dr.Rugo chaired the advisory panel of OncLive's "Giants of Cancer Care" award program.

Dr.Rugo was lead investigator on research that investigated the hair-preserving properties of cold caps for patients undergoing chemotherapy.

Along with her studies she is also an active clinician who gives lectures locally as well as internationally and nationally.

In 2025, Dr.Rugo was named division chief of breast medical oncology for City of Hope, a cancer treatment and research group. Provided by Wikipedia
Showing 1 - 9 results of 9 for search 'Hope S. Rugo', query time: 0.03s Refine Results
  1. 1
    Real-world effectiveness of palbociclib plus an aromatase inhibitor in HR+/HER2− MBC patients living in disadvantaged neighborhoods

    Real-world effectiveness of palbociclib plus an aromatase inhibitor in HR+/HER2− MBC patients living in disadvantaged neighborhoods by Filipa Lynce, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Raymond Liu, Hope S. Rugo

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Efficacy of sacituzumab govitecan versus treatment of physician’s choice in previously treated HR+ and HER2− mBC: a meta-analysis of TROPiCS-02 and EVER-132-002 trials

    Efficacy of sacituzumab govitecan versus treatment of physician’s choice in previously treated HR+ and HER2− mBC: a meta-analysis of TROPiCS-02 and EVER-132-002 trials by Oleg Gluz, Binghe Xu, Rita Nanda, Anandaroop Dasgupta, Ankita Kaushik, Wendy Verret, Akanksha Sharma, Barinder Singh, Hope S. Rugo

    Published 2025-03-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Role of Fcγ receptors in HER2-targeted breast cancer therapy

    Role of Fcγ receptors in HER2-targeted breast cancer therapy by Hope S Rugo, Antonino Musolino, William J Gradishar, Jeffrey L Nordstrom, Edwin P Rock, Fernanda Arnaldez, Mark D Pegram

    Published 2022-01-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Expert consensus on treating HR+/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists

    Expert consensus on treating HR+/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists by Hope S. Rugo, Aditya Bardia, William J. Gradishar, Erika P. Hamilton, Sara A. Hurvitz, Komal Jhaveri, Reshma Mahtani, Sara M. Tolaney

    Published 2025-08-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2− Metastatic Breast Cancer

    Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2− Metastatic Breast Cancer by Hope S. Rugo, Aditya Bardia, Peter Schmid, Sara M. Tolaney, Anandaroop Dasgupta, Ankita Kaushik, Wendy Verret, Marine Gosset, Adam Brufsky, Javier Cortés, Frederik Marmé

    Published 2025-03-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR+/HER2− Metastatic Breast Cancer

    Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR+/HER2− Metastatic Breast Cancer by Adam M. Brufsky, Rickard Sandin, Stella Stergiopoulos, Connie Chen, Siddharth Karanth, Benjamin Li, Elizabeth Esterberg, Doris Makari, Sean D. Candrilli, Ravi K. Goyal, Hope S. Rugo

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)

    Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with H... by Laura A. Huppert, Reshma Mahtani, Samantha Fisch, Naomi Dempsey, Sarah Premji, Angelina Raimonde, Saya Jacob, Laura Quintal, Michelle Melisko, Jo Chien, Ana Sandoval, Lauren Carcas, Manmeet Ahluwalia, Natasha Harpalani, Jenna Hoppenworth, Anne Blaes, Kelly Blum, Mi-Ok Kim, Dame Idossa, Ruta Rao, Karthik V. Giridhar, Hope S. Rugo

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study

    Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study by Sung-Bae Kim, Hope S Rugo, Sara A Hurvitz, Hong-Tai Chang, Chiun-Sheng Huang, Su-Hua Lee, Jung-Tung Hung, Shir-Hwa Ueng, Shin-Cheh Chen, Alice L Yu, Ling-Ming Tseng, Louis W C Chow, Ming-Feng Hou, Richard B Schwab, James L Murray, Hsien-Kun Chang, Chwen-Cheng Chen

    Published 2020-10-01
    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    Tumor cell-adipocyte gap junctions activate lipolysis and contribute to breast tumorigenesis

    Tumor cell-adipocyte gap junctions activate lipolysis and contribute to breast tumorigenesis by Jeremy Williams, Roman Camarda, Serghei Malkov, Lisa J. Zimmerman, Suzanne Manning, Dvir Aran, Andrew Beardsley, Daniel Van de Mark, Rachel Nakagawa, Yong Chen, Charles Berdan, Sharon M. Louie, Celine Mahieu, Daphne Superville, Juliane Winkler, Elizabeth Willey, Erica J. Hutchins, John D. Gagnon, Seda Kilinc Avsaroglu, Kosaku Shinoda, Matthew Gruner, Hiroshi Nishida, K. Mark Ansel, Zena Werb, Daniel K. Nomura, Shingo Kajimura, Atul J. Butte, Melinda E. Sanders, Daniel C. Liebler, Hope S. Rugo, Gregor Krings, John A. Shepherd, Andrei Goga

    Published 2025-08-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: